-DOCSTART- -X- O
Respiratory -X- _ O
viral -X- _ O
infections -X- _ O
cause -X- _ O
mild -X- _ O
to -X- _ O
severe -X- _ O
diseases -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
common -X- _ O
cold -X- _ O
, -X- _ O
bronchiolitis -X- _ O
and -X- _ O
pneumonia -X- _ O
and -X- _ O
are -X- _ O
associated -X- _ O
with -X- _ O
substantial -X- _ O
burden -X- _ O
for -X- _ O
society. -X- _ O
To -X- _ O
test -X- _ O
new -X- _ O
molecules -X- _ O
for -X- _ O
shortening -X- _ O
, -X- _ O
alleviating -X- _ O
the -X- _ O
diseases -X- _ O
or -X- _ O
to -X- _ O
develop -X- _ O
new -X- _ O
therapies -X- _ O
, -X- _ O
relevant -X- _ O
human -X- _ O
in -X- _ O
vitro -X- _ O
models -X- _ O
are -X- _ O
mandatory. -X- _ O
MucilAir™ -X- _ B-Patient
, -X- _ O
a -X- _ O
human -X- _ O
standardized -X- _ O
air-liquid -X- _ O
interface -X- _ O
3D -X- _ O
airway -X- _ O
epithelial -X- _ O
culture -X- _ O
holds -X- _ O
in -X- _ O
vitro -X- _ O
specific -X- _ O
mechanisms -X- _ O
to -X- _ O
counter -X- _ O
invaders -X- _ O
comparable -X- _ O
to -X- _ O
the -X- _ O
in -X- _ O
vivo -X- _ O
situation -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
mucus -X- _ O
production -X- _ O
, -X- _ O
mucociliary -X- _ O
clearance -X- _ O
, -X- _ O
and -X- _ O
secretion -X- _ O
of -X- _ O
defensive -X- _ O
molecules. -X- _ O
The -X- _ O
objective -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
test -X- _ O
the -X- _ O
relevance -X- _ O
of -X- _ O
such -X- _ O
a -X- _ O
model -X- _ O
for -X- _ O
the -X- _ O
discovery -X- _ O
and -X- _ O
validation -X- _ O
of -X- _ O
antiviral -X- _ B-Intervention
drugs. -X- _ I-Intervention
Fully -X- _ B-Patient
differentiated -X- _ I-Patient
3D -X- _ I-Patient
nasal -X- _ I-Patient
epithelium -X- _ I-Patient
cultures -X- _ I-Patient
were -X- _ I-Patient
inoculated -X- _ I-Patient
with -X- _ I-Patient
picornaviruses -X- _ I-Patient
, -X- _ I-Patient
a -X- _ I-Patient
coronavirus -X- _ I-Patient
and -X- _ I-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
viruses -X- _ I-Patient
in -X- _ O
the -X- _ O
absence -X- _ B-Comparison
or -X- _ O
in -X- _ O
the -X- _ O
presence -X- _ B-Intervention
of -X- _ I-Intervention
reference -X- _ I-Intervention
antiviral -X- _ I-Intervention
drugs. -X- _ I-Intervention
Results -X- _ O
showed -X- _ O
that -X- _ O
, -X- _ O
rupintrivir -X- _ B-Outcome
efficiently -X- _ I-Outcome
inhibits -X- _ I-Outcome
the -X- _ I-Outcome
replication -X- _ I-Outcome
of -X- _ I-Outcome
respiratory -X- _ I-Outcome
picornaviruses -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
dose -X- _ I-Outcome
dependent -X- _ I-Outcome
manner -X- _ I-Outcome
and -X- _ I-Outcome
prevents -X- _ I-Outcome
the -X- _ I-Outcome
impairment -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
mucociliary -X- _ I-Outcome
clearance. -X- _ I-Outcome
Similarly -X- _ O
, -X- _ O
oseltamivir -X- _ B-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
replication -X- _ I-Outcome
of -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
viruses -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
dose -X- _ I-Outcome
dependent -X- _ I-Outcome
manner -X- _ I-Outcome
and -X- _ I-Outcome
prevented -X- _ I-Outcome
the -X- _ I-Outcome
impairment -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
epithelial -X- _ I-Outcome
barrier -X- _ I-Outcome
function -X- _ I-Outcome
and -X- _ I-Outcome
cytotoxicity -X- _ I-Outcome
until -X- _ I-Outcome
4 -X- _ I-Outcome
days -X- _ I-Outcome
of -X- _ I-Outcome
infection. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
we -X- _ O
found -X- _ O
that -X- _ O
Rhinovirus -X- _ B-Outcome
B14 -X- _ I-Outcome
, -X- _ I-Outcome
C15 -X- _ I-Outcome
and -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
( -X- _ I-Outcome
H1N1 -X- _ I-Outcome
) -X- _ I-Outcome
induce -X- _ I-Outcome
significant -X- _ I-Outcome
increase -X- _ I-Outcome
of -X- _ I-Outcome
β -X- _ I-Outcome
Defensins -X- _ I-Outcome
2 -X- _ I-Outcome
and -X- _ I-Outcome
Cathelicidin -X- _ I-Outcome
release -X- _ I-Outcome
with -X- _ I-Outcome
different -X- _ I-Outcome
time -X- _ I-Outcome
course. -X- _ I-Outcome
These -X- _ O
results -X- _ O
reveal -X- _ O
that -X- _ O
a -X- _ O
large -X- _ O
panel -X- _ O
of -X- _ O
epithelial -X- _ O
functions -X- _ O
is -X- _ O
modified -X- _ O
upon -X- _ O
viral -X- _ O
infection -X- _ O
and -X- _ O
validate -X- _ O
MucilAir™ -X- _ O
as -X- _ O
a -X- _ O
pertinent -X- _ O
tool -X- _ O
for -X- _ O
pre-clinical -X- _ O
antiviral -X- _ O
drug -X- _ O
testing -X- _ O
. -X- _ O

